Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0680 (AMP-514) in Advanced Malignancies
NCT02013804Phase 1Completed
- Sponsor
- MedImmune
- Start
- Dec 2013
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MEDI0680 in melanoma and clear cell renal cell carcinoma (ccRCC), sponsored by MedImmune. Primary endpoints: Safety and Tolerability at 1 year and Maximum Tolerated Dose at 1 year. Started Dec 2013; status: completed.
02
Drugs
MEDI0680
03
Conditions
melanomaclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02013804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013804.